Anticoagulation and antiplatelet therapy in urological practice: ICUD/AUA review paper

Daniel J. Culkin, Emilio J. Exaire, David Green, Mark S. Soloway, Andreas J. Gross, Maheshbhai R. Desai, James R. White, Deborah J. Lightner

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Purpose Given the lack of urology specific directives for the periprocedural management of anticoagulant and antiplatelet medications, the AUA (American Urological Association) and ICUD (International Consultation on Urological Disease) named an international multidisciplinary panel to develop consensus based recommendations. Materials and Methods A systematic literature review was queried by a methodologist for 3 questions. 1) When and in whom can anticoagulant/antiplatelet prophylaxis be stopped in preparation for surgery? 2) What procedures can be safely performed without discontinuing anticoagulant/antiplatelet prophylaxis? 3) What periprocedural strategies can adequately balance the risk of major surgical bleeding vs the risk of major thrombotic event? Hematology and cardiology guidelines, and 79 articles were selected for full review. Results Multidisciplinary management of anticoagulant/antiplatelet medications for patients with recent thromboembolic events, mechanical cardiac valves, atrial fibrillation and cardiac stents would reduce the high morbidity and mortality of inexpertly discontinuing or modifying these lifesaving therapies. No elective procedures requiring interruption of dual antiplatelet therapies should be performed with a recent bare metal or drug eluting stent. The risk of significant bleeding complications is low for patients who require continuation of aspirin for ureteroscopy, transrectal prostate biopsies, laser prostate outlet procedures and percutaneous renal biopsy. Open extirpative prostate and renal procedures can be performed with a low risk of significant hemorrhage for patients on aspirin and those requiring heparin based bridging strategies. The current literature does not give direction on the timing of the resumption of anticoagulant/antiplatelet prophylaxis other than that it be resumed as soon as the risk of bleeding has decreased. Conclusions A total of 2,674 nonredundant article abstracts were obtained and assessed for relevance to key questions outlined by the panel. Overall 106 articles were selected for full text review and accepted or rejected based on the relation to the topic, quality of information and key questions. A total of 79 articles were accepted. Reasons for rejection (27 articles) included abstract only (12), insufficient information or unrelated to topic (13) and redundancy (2). We extracted study design, patient population, followup period and results from accepted articles, which serve as the evidence base.

Original languageEnglish
Pages (from-to)1026-1034
Number of pages9
JournalJournal of Urology
Volume192
Issue number4
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Urologic Diseases
Anticoagulants
Referral and Consultation
Hemorrhage
Prostate
Aspirin
Ureteroscopy
Kidney
Biopsy
Therapeutics
Drug-Eluting Stents
Heart Valves
Urology
Hematology
Cardiology
Atrial Fibrillation
Stents
Heparin
Lasers
Metals

Keywords

  • anticoagulants
  • platelet aggregation inhibitors
  • practice guideline
  • thromboembolism
  • urologic surgical procedures

ASJC Scopus subject areas

  • Urology
  • Medicine(all)

Cite this

Culkin, D. J., Exaire, E. J., Green, D., Soloway, M. S., Gross, A. J., Desai, M. R., ... Lightner, D. J. (2014). Anticoagulation and antiplatelet therapy in urological practice: ICUD/AUA review paper. Journal of Urology, 192(4), 1026-1034. https://doi.org/10.1016/j.juro.2014.04.103

Anticoagulation and antiplatelet therapy in urological practice : ICUD/AUA review paper. / Culkin, Daniel J.; Exaire, Emilio J.; Green, David; Soloway, Mark S.; Gross, Andreas J.; Desai, Maheshbhai R.; White, James R.; Lightner, Deborah J.

In: Journal of Urology, Vol. 192, No. 4, 01.01.2014, p. 1026-1034.

Research output: Contribution to journalArticle

Culkin, DJ, Exaire, EJ, Green, D, Soloway, MS, Gross, AJ, Desai, MR, White, JR & Lightner, DJ 2014, 'Anticoagulation and antiplatelet therapy in urological practice: ICUD/AUA review paper', Journal of Urology, vol. 192, no. 4, pp. 1026-1034. https://doi.org/10.1016/j.juro.2014.04.103
Culkin DJ, Exaire EJ, Green D, Soloway MS, Gross AJ, Desai MR et al. Anticoagulation and antiplatelet therapy in urological practice: ICUD/AUA review paper. Journal of Urology. 2014 Jan 1;192(4):1026-1034. https://doi.org/10.1016/j.juro.2014.04.103
Culkin, Daniel J. ; Exaire, Emilio J. ; Green, David ; Soloway, Mark S. ; Gross, Andreas J. ; Desai, Maheshbhai R. ; White, James R. ; Lightner, Deborah J. / Anticoagulation and antiplatelet therapy in urological practice : ICUD/AUA review paper. In: Journal of Urology. 2014 ; Vol. 192, No. 4. pp. 1026-1034.
@article{eb44743d1299421190f720188576d81b,
title = "Anticoagulation and antiplatelet therapy in urological practice: ICUD/AUA review paper",
abstract = "Purpose Given the lack of urology specific directives for the periprocedural management of anticoagulant and antiplatelet medications, the AUA (American Urological Association) and ICUD (International Consultation on Urological Disease) named an international multidisciplinary panel to develop consensus based recommendations. Materials and Methods A systematic literature review was queried by a methodologist for 3 questions. 1) When and in whom can anticoagulant/antiplatelet prophylaxis be stopped in preparation for surgery? 2) What procedures can be safely performed without discontinuing anticoagulant/antiplatelet prophylaxis? 3) What periprocedural strategies can adequately balance the risk of major surgical bleeding vs the risk of major thrombotic event? Hematology and cardiology guidelines, and 79 articles were selected for full review. Results Multidisciplinary management of anticoagulant/antiplatelet medications for patients with recent thromboembolic events, mechanical cardiac valves, atrial fibrillation and cardiac stents would reduce the high morbidity and mortality of inexpertly discontinuing or modifying these lifesaving therapies. No elective procedures requiring interruption of dual antiplatelet therapies should be performed with a recent bare metal or drug eluting stent. The risk of significant bleeding complications is low for patients who require continuation of aspirin for ureteroscopy, transrectal prostate biopsies, laser prostate outlet procedures and percutaneous renal biopsy. Open extirpative prostate and renal procedures can be performed with a low risk of significant hemorrhage for patients on aspirin and those requiring heparin based bridging strategies. The current literature does not give direction on the timing of the resumption of anticoagulant/antiplatelet prophylaxis other than that it be resumed as soon as the risk of bleeding has decreased. Conclusions A total of 2,674 nonredundant article abstracts were obtained and assessed for relevance to key questions outlined by the panel. Overall 106 articles were selected for full text review and accepted or rejected based on the relation to the topic, quality of information and key questions. A total of 79 articles were accepted. Reasons for rejection (27 articles) included abstract only (12), insufficient information or unrelated to topic (13) and redundancy (2). We extracted study design, patient population, followup period and results from accepted articles, which serve as the evidence base.",
keywords = "anticoagulants, platelet aggregation inhibitors, practice guideline, thromboembolism, urologic surgical procedures",
author = "Culkin, {Daniel J.} and Exaire, {Emilio J.} and David Green and Soloway, {Mark S.} and Gross, {Andreas J.} and Desai, {Maheshbhai R.} and White, {James R.} and Lightner, {Deborah J.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.juro.2014.04.103",
language = "English",
volume = "192",
pages = "1026--1034",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Anticoagulation and antiplatelet therapy in urological practice

T2 - ICUD/AUA review paper

AU - Culkin, Daniel J.

AU - Exaire, Emilio J.

AU - Green, David

AU - Soloway, Mark S.

AU - Gross, Andreas J.

AU - Desai, Maheshbhai R.

AU - White, James R.

AU - Lightner, Deborah J.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Purpose Given the lack of urology specific directives for the periprocedural management of anticoagulant and antiplatelet medications, the AUA (American Urological Association) and ICUD (International Consultation on Urological Disease) named an international multidisciplinary panel to develop consensus based recommendations. Materials and Methods A systematic literature review was queried by a methodologist for 3 questions. 1) When and in whom can anticoagulant/antiplatelet prophylaxis be stopped in preparation for surgery? 2) What procedures can be safely performed without discontinuing anticoagulant/antiplatelet prophylaxis? 3) What periprocedural strategies can adequately balance the risk of major surgical bleeding vs the risk of major thrombotic event? Hematology and cardiology guidelines, and 79 articles were selected for full review. Results Multidisciplinary management of anticoagulant/antiplatelet medications for patients with recent thromboembolic events, mechanical cardiac valves, atrial fibrillation and cardiac stents would reduce the high morbidity and mortality of inexpertly discontinuing or modifying these lifesaving therapies. No elective procedures requiring interruption of dual antiplatelet therapies should be performed with a recent bare metal or drug eluting stent. The risk of significant bleeding complications is low for patients who require continuation of aspirin for ureteroscopy, transrectal prostate biopsies, laser prostate outlet procedures and percutaneous renal biopsy. Open extirpative prostate and renal procedures can be performed with a low risk of significant hemorrhage for patients on aspirin and those requiring heparin based bridging strategies. The current literature does not give direction on the timing of the resumption of anticoagulant/antiplatelet prophylaxis other than that it be resumed as soon as the risk of bleeding has decreased. Conclusions A total of 2,674 nonredundant article abstracts were obtained and assessed for relevance to key questions outlined by the panel. Overall 106 articles were selected for full text review and accepted or rejected based on the relation to the topic, quality of information and key questions. A total of 79 articles were accepted. Reasons for rejection (27 articles) included abstract only (12), insufficient information or unrelated to topic (13) and redundancy (2). We extracted study design, patient population, followup period and results from accepted articles, which serve as the evidence base.

AB - Purpose Given the lack of urology specific directives for the periprocedural management of anticoagulant and antiplatelet medications, the AUA (American Urological Association) and ICUD (International Consultation on Urological Disease) named an international multidisciplinary panel to develop consensus based recommendations. Materials and Methods A systematic literature review was queried by a methodologist for 3 questions. 1) When and in whom can anticoagulant/antiplatelet prophylaxis be stopped in preparation for surgery? 2) What procedures can be safely performed without discontinuing anticoagulant/antiplatelet prophylaxis? 3) What periprocedural strategies can adequately balance the risk of major surgical bleeding vs the risk of major thrombotic event? Hematology and cardiology guidelines, and 79 articles were selected for full review. Results Multidisciplinary management of anticoagulant/antiplatelet medications for patients with recent thromboembolic events, mechanical cardiac valves, atrial fibrillation and cardiac stents would reduce the high morbidity and mortality of inexpertly discontinuing or modifying these lifesaving therapies. No elective procedures requiring interruption of dual antiplatelet therapies should be performed with a recent bare metal or drug eluting stent. The risk of significant bleeding complications is low for patients who require continuation of aspirin for ureteroscopy, transrectal prostate biopsies, laser prostate outlet procedures and percutaneous renal biopsy. Open extirpative prostate and renal procedures can be performed with a low risk of significant hemorrhage for patients on aspirin and those requiring heparin based bridging strategies. The current literature does not give direction on the timing of the resumption of anticoagulant/antiplatelet prophylaxis other than that it be resumed as soon as the risk of bleeding has decreased. Conclusions A total of 2,674 nonredundant article abstracts were obtained and assessed for relevance to key questions outlined by the panel. Overall 106 articles were selected for full text review and accepted or rejected based on the relation to the topic, quality of information and key questions. A total of 79 articles were accepted. Reasons for rejection (27 articles) included abstract only (12), insufficient information or unrelated to topic (13) and redundancy (2). We extracted study design, patient population, followup period and results from accepted articles, which serve as the evidence base.

KW - anticoagulants

KW - platelet aggregation inhibitors

KW - practice guideline

KW - thromboembolism

KW - urologic surgical procedures

UR - http://www.scopus.com/inward/record.url?scp=84921991312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921991312&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2014.04.103

DO - 10.1016/j.juro.2014.04.103

M3 - Article

C2 - 24859439

AN - SCOPUS:84921991312

VL - 192

SP - 1026

EP - 1034

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 4

ER -